Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Loading zone tomorrow am
Big news coming tomorrow or Friday! Big news!
Considering the below facts are true coupled with a untapped multi billion market opportunity (side note: Look up Flexogenix regenerative medicine. That company makes millions doing similar stuff; cash pay model and each office cost $1M to build out) how can you even argue it won't go to the moon. They climbed out from under a big number and now cash flow positive. WOW!
Financial highlights from 2016 include:
Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M, or 23.8%, from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company's history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015
Aka losers lounge
This group reminds me of a funeral! God Bless!
That's why stocks movin
$1 would be nice
Northern Colorado Presents PMCB at ACS this weekend!!!
https://globenewswire.com/news-release/2016/11/14/889653/0/en/University-of-Northern-Colorado-Presenting-PharmaCyte-Biotech-s-Cannabis-Research-at-the-2017-American-Chemical-Society-National-Meeting.html
Date: April 2-6
https://www.acs.org/content/acs/en/meetings.html
Northern Colorado to present results from PMCB testing this weekend. Or lack therof this weekend.
Big dump coming this week
Caught in this pump trash...
Or he's 70
Love how peeps here think this company is legit.... buy more
How many chums got caught holding the bag?
Here comes the crash .05 by next week
Did they even meet with the FDA for a preIND? I feel based on some information out that the ore IND was held with their CRO or TD2. Its confusing because KW was the only one to say FDA and I don't believe him anymore
If you buy this company above .05 simply put you are a fool.
I'd love to repost this Pham come next week. Is that ok
Technology is fools gold. I believe based on how cell encapsulation works that it will spread cancer within the body. They talk about it discharging waste but within that waste there are cancer cells that will float around and spread
Loading ZONE Pham
Someone please explain the difference between optimistic and ignorance as it relates to PMCB
KW is preparing to sell. That's why the PR
If you can't give a timeline it is not "soon" per KW and the next step is not "to file an IND" per KW. Patience
With a press release like today. Get out while you still can
Had a dream last night the first pop goes to 30 cents
I was wondering you bought
PPS will be 7/8 by end of mo and next month 4/5.
KW is buying time
Dilution is like a tax increase. This one is relatively small.
You make me want to sell :)
Does an IND submission and approval change your mind?
What would a company pay for this technology pre IND?
What would a company pay when an IND is approved?
Agreed. Although a breakthrough in cancer in increased quality of life which PMCB offers.
The cure for cancer has already been found, unknowingly of course. It's the delivery system that has not been explored. This will bring back so many old drugs back for new testing.
"Don't follow the drugs, follow the money." Open your mind Bear
For what's it worth:
"We are the manufacturer and registered trade mark owner of Cell-in-a-Box® and PharmaCyte has licensed this technology from us for specific applications."
Best wishes,
John
Austrianova Singapore Pte Ltd
Dr. John A. Dangerfield / COO
dangerfield@sgaustria.com
I was curious to see what organizations think about PMCB and this is ones response.
Thank you for contacting the Pancreatic Cancer Action Network. My name is Celeste and I am a Patient Central Associate. I would be happy to assist you.
We are aware of the research that is being conducted by PharmaCyte Biotech. I have provided some information below on the topic.
Please note that I am not a medical professional, nor does the Pancreatic Cancer Action Network have one on staff. Therefore, I am unable to provide any medical advice or treatment recommendations. The information below is intended to serve as an educational resource.
PharmaCyte Biotech acquired a technology that involves what they call encapsulated living cells, as a treatment for pancreatic cancer.
On their website they mention that there was a Phase II trial that was completed in pancreatic cancer patients. Below I have provided a link to the abstract for that trial.
Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer
I have also provided below a link to another article discussing this therapy.
Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
Also on their website, PharmaCyte Biotech mentions that they will be conducting a pancreatic cancer clinical trial sometime soon, but they do not provide any specific information regarding the trial or when it will open to patient enrollment. We are not aware of any currently active trials here in the United States that are testing this technology.
I have included an article below that that discusses how the FDA Granted Orphan Drug Designation to PharmaCyte Biotech (previously Nuvilex) for pancreatic cancer treatment.
https://globenewswire.com/news-release/2014/12/22/693421/10113176/en/FDA-Grants-Orphan-Drug-Designation-to-Nuvilex-for-Pancreatic-Cancer-Treatment.html
This therapy is real as it is being investigated in the clinical trial setting. However, until this therapy completes the clinical trials process (Phase I, Phase II, and Phase III testing), we will not know whether or not this therapy is safe and effective in treating pancreatic cancer.
As you mentioned that you have a family history of cancer, I would like to mention that we have information on risk factors and genetic disorders associated with pancreatic cancer, along with information on research studies that high-risk individuals can join for potential early detection and to advance research. If you would like to receive this information, please let me know.
We also have a complimentary basic pancreatic cancer education packet. If you would like to receive it, please provide your mailing address.
I hope you find this information useful, James. If you have any further questions or need additional resources, please do not hesitate to contact me. I can be reached Monday – Friday, 7 a.m. to 3 p.m., Pacific Time toll-free at 877.272.6226, or by email at coneill@pancan.org.
Sincerely,
Celeste
______________________________________
Celeste O’Neill
Patient Central Associate
Pancreatic Cancer Action Network National Office
1500 Rosecrans Avenue, Suite 200
Manhattan Beach, CA 90266
Phone: 310.725.0025
Toll-Free: 877.272.6226
Fax: 310.725.0029
www.pancan.org
Information provided by the Pancreatic Cancer Action Network, Inc. (“PanCAN”) is not a substitute for medical advice, diagnosis, treatment or other health care services. PanCAN may provide information to you about physicians, products, services, clinical trials or treatments related to pancreatic cancer, but PanCAN does not recommend nor endorse any particular health care resource. In addition, please note that any personal information you provide to PanCAN's associates during telephone and/or email communications may be stored and used to help PanCAN achieve its mission of assisting patients with, and finding cures and treatments for, pancreatic cancer. Stored constituent information may be used to inform PanCAN programs and activities. Information also may be provided in aggregate or limited formats to third parties to guide future pancreatic cancer research and treatment efforts. PanCAN will not provide personal directly identifying information (such as your name or contact information) to such third parties without your prior written consent unless required or permitted by law to do so.
ADVANCE RESEARCH | SUPPORT PATIENTS | CREATE HOPE
Somebody sell already ??
Don't worry... this stocks got a least one more pop. May never get your Mil tho.
Remember when stock was up today on good news then came back... Manipulation at its finest. Stayed tuned more to come ;)
Things are not looking good. Bad news coming
Don't forget UNoC is allegedly presenting PMCB on April 2nd at ACSN. No news here is bad news.